Log In
Print this Print this

Treximet, sumatriptan/naproxen

Also known as: formerly Trexima

  Manage Alerts
Collapse Summary General Information
Company Pozen Inc.
DescriptionCombination of sumatriptan and naproxen sodium
Molecular Target Serotonin (5-HT1B) receptor ; Serotonin (5-HT1D) receptor
Mechanism of ActionSerotonin (5-HT1B) receptor agonist
Therapeutic ModalitySmall molecule: Combination
Latest Stage of DevelopmentMarketed
Standard IndicationMigraine
Indication DetailsTreat acute migraine; Treat acute migraine, with or without aura, in adults; Treat migraine in adolescents; Treat migraine in patients with a poor response or intolerance to short-acting triptan treatment; Treat probable migraine
Regulatory Designation U.S. - Priority Review (Treat migraine in adolescents)
Partner GlaxoSmithKline plc; Pernix Therapeutics Holdings Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today